Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Metastasis, Breast Cancer
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated…
- Trial name
- ATTAIN (NCT02915744)
- Testing
- NKTR-102, Eribulin, Ixabepilone
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
The purpose of this study is to see if capecitabine can be taken safely with different doses of lapatinib in patients with HER-2 positive breast cancer involving brain (brain metastases) and/or in spinal fluid (leptomeningeal…
- Trial name
- NCT02650752
- Testing
- Lapatinib in Tandem With Capecitabine
- Where
- 9 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Triple Negative Breast Cancer
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
The purpose of this study is to see how effective the combination of the two chemotherapy drugs (carboplatin and nab-paclitaxel) are when added to a third drug, pembrolizumab.
- Trial name
- NCT03121352
- Testing
- Carboplatin, Nab-paclitaxel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer Stage IV, Oligometastatic Disease
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy…
- Trial name
- TAORMINA (NCT05377047)
- Testing
- SABR
- Where
- 19 sites in Ireland, Israel and 4 more
- Volunteers
- 345 people
- Sponsor
- Vastra Gotaland Region
Breast Cancer
The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)
This is an open-label, multinational, randomized, multicenter trial designed to compare pegylated liposomal doxorubicin with capecitabine as first line chemotherapy of metastatic breast cancer.
- Trial name
- NCT00266799
- Testing
- Pegylated liposomal doxorubicin (SCH 200746), Capecitabine
- Volunteers
- 210 people
- Sponsor
- Merck Sharp & Dohme LLC
Central Nervous System (CNS) Metastases, Breast Cancer
A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
Approximately 5-15% breast cancer patients develop brain metastases. Current local treatments (surgery/radiotherapy) are associated with significant complications, and systemic treatments have limited efficacy.
- Trial name
- BCBM006 (NCT07653893)
- Testing
- No Interventions
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Breast Cancer, Chemotherapeutic Agent Toxicity
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by…
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
- Trial name
- NCT00754767
- Testing
- L-carnitine L-tartrate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- HealthPartners Institute
Locally Advanced Breast Cancer, Metastatic Breast Cancer
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
The main purpose of this study is to evaluate the effectiveness of inavolisib based regimen in participants with endocrine-resistant, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-mutated…
- Trial name
- reaINAVO (NCT07347600)
- Testing
- Inavolisib, Palbociclib, Fulvestrant
- Where
- 32 sites in China
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Leptomeningeal Metastases
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
Leptomeningeal metastases (LM) is a lethal complication of malignant tumors, characterized by tumor cell invasion and proliferation within the subarachnoid space.
- Trial name
- NCT06462092
- Testing
- Sacituzumab Govitecan, Pemetrexed
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Guangzhou Medical University
Breast Cancer Female
The Role of Magnetic Resonance Imaging in Assessment of Axillary Lymph Nodes Metastasis in Breast Cancer Patients.
Breast cancer is the most common cancer among women worldwide.The main cause of cancer related death is the invasion and metastasis. The usual site of spread outside the breast is to lymph nodes in the axilla.
- Trial name
- NCT03163316
- Testing
- Unenhanced magnetic resonance imaging.
- Where
- 2 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Stage IV Breast Cancer
Vaccination of High Risk Breast Cancer Patients
Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.
- Trial name
- NCT01390064
- Testing
- Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arkansas
Breast Cancer
A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to bevacizumab and paclitaxel in patients with HR-positive…
- Trial name
- AMBITION (NCT04732598)
- Testing
- Paclitaxel + bevacizumab therapy, Paclitaxel + bevacizumab + atezolizumab
- Where
- Japan
- Volunteers
- 281 people
- Sponsor
- Japanese Foundation for Cancer Research
Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Trial name
- NCT03763604
- Testing
- Abemaciclib
- Where
- 160 sites in Australia, Canada and 12 more
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
In this Phase II trial, the investigators will evaluate the combination of gemcitabine, carboplatin, and panitumumab in the treatment of patients with metastatic triple-negative breast cancer.
- Trial name
- NCT00894504
- Testing
- Panitumumab, Carboplatin, Gemcitabine
- Where
- 17 sites in United States
- Volunteers
- 71 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, Locally Advanced Breast Cancer
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
- Conditions
- Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
- Trial name
- OPERA-02 (NCT07085767)
- Testing
- Palazestrant, Ribociclib, Letrozole
- Where
- 200 sites in United States, Australia and 21 more
- Volunteers
- 1,000 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Metastatic Breast Cancer
Ixabepilone + Carboplatin Metastatic Breast Cancer
Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+ and triple negative breast cancer. Ixabepilone has substantial antitumor activity in taxane-refractory patients and novel combinations are…
- Trial name
- NCT01075100
- Testing
- Ixabepilone, Carboplatin
- Where
- 59 sites in United States
- Volunteers
- 103 people
- Sponsor
- US Oncology Research
Bone Metastases, Breast Cancer
Merestinib on Bone Metastases in Subjects With Breast Cancer
This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.
- Trial name
- NCT03292536
- Testing
- Merestinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Utah
Metastatic Breast Cancer
Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer
To determine the safety and tolerability of Oraxol as compared to IV paclitaxel in metastatic breast cancer
- Trial name
- NCT02594371
- Testing
- Oraxol, IV paclitaxel
- Where
- 45 sites in Argentina, Chile and 8 more
- Volunteers
- 402 people
- Sponsor
- Athenex, Inc.
Neoplasms, Neoplasm Metastasis
A Study of AK-01 (LY3295668) in Solid Tumors
This two-part study consists of a phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either small cell lung cancer, breast cancer and/or…
- Conditions
- Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT03092934
- Testing
- LY3295668
- Where
- 3 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.